Details of the Drug Combination

General Information of Drug Combination (ID: DCCCLQG)

Drug Combination Name
RAF265 CHLOROXINE
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs RAF265   DMC56T4 CHLOROXINE   DMFZBMQ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SU-DIPG-XIII
Zero Interaction Potency (ZIP) Score: 5.872
Bliss Independence Score: 14.045
Loewe Additivity Score: 1.997
LHighest Single Agent (HSA) Score: 4.22

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of RAF265
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [2]
RAF265 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of CHLOROXINE
Disease Entry ICD 11 Status REF
Erythema ME64.0 Approved [3]
Pityriasis simplex N.A. Approved [4]
CHLOROXINE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Opioid receptor kappa (OPRK1) TTQW87Y OPRK_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
CHLOROXINE Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases ADR [7]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases ADR [7]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases ADR [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5674).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Chloroxine FDA Label
5 RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5.
6 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.